2026 대한장연구학회 궤양성 대장염 내과적 치료 가이드라인

@article{김20262026,
  title = {{2026 대한장연구학회 궤양성 대장염 내과적 치료 가이드라인}},
  author = {동현 김 and 승민 홍 and 승용 신 and 준화 배 and 은미 송 and 지은 김 and 영주 양 and 지영 윤 and 상범 강 and 은수 김 and 성은 김 and 성중 김 and 준 이 and 수영 나 and 수정 박 and 상형 박 and 명하 김 and 미영 최 and 종률 이 and 세진 백 and 원 문 and 성애 정 and 대한장연구학회 가이드라인위원회},
  journal = {The Korean Journal of Gastroenterology},
  year = {2026},
  month = oct,
  doi = {10.4166/kjg.2026.091},
  url = {https://doi.org/10.4166/kjg.2026.091},
  note = {CC BY-NC 4.0},
}

TY  - JOUR
TI  - 2026 대한장연구학회 궤양성 대장염 내과적 치료 가이드라인
AU  - 동현 김
AU  - 승민 홍
AU  - 승용 신
AU  - 준화 배
AU  - 은미 송
AU  - 지은 김
AU  - 영주 양
AU  - 지영 윤
AU  - 상범 강
AU  - 은수 김
AU  - 성은 김
AU  - 성중 김
AU  - 준 이
AU  - 수영 나
AU  - 수정 박
AU  - 상형 박
AU  - 명하 김
AU  - 미영 최
AU  - 종률 이
AU  - 세진 백
AU  - 원 문
AU  - 성애 정
AU  - 대한장연구학회 가이드라인위원회
PY  - 2026
DA  - 2026/10/25
JO  - The Korean Journal of Gastroenterology
DO  - 10.4166/kjg.2026.091
UR  - https://doi.org/10.4166/kjg.2026.091
AB  - Ulcerative colitis (UC) is a chronic immune-mediated inflammatory bowel disease with an expanding therapeutic landscape and increasing clinical complexity. This guideline was developed by the Korean Association for the Study of Intestinal Diseases (KASID) to provide updated, evidence-based recommendations for the medical management of adult patients with UC in Korea. Guideline development used the GRADE-ADOLOPMENT approach, with source guidelines appraised using AGREE II. Key questions were formulated using the PICO framework, source guidelines and consensus documents published from 2017 through 2025 were appraised, and targeted literature searches covering January 2020 through April 2026 were conducted in PubMed, Embase, the Cochrane Library, and KoreaMed. The guideline addresses induction and maintenance therapy for mild-to-moderate and moderate-to-severe UC, management of acute severe UC, indications for surgery, use of biosimilars and subcutaneous formulations, and treatment optimization and sequencing. Recommendations were formulated based on structured evidence review and Evidence-to-Decision considerations, and were finalized through a modified Delphi consensus process and external review. The final recommendations emphasize objective disease control, individualized treatment selection, timely escalation or surgery in acute severe UC, and shared decision-making based on efficacy, safety, comorbidities, prior treatment exposure, patient preference, drug accessibility, and the Korean healthcare context. This guideline is intended to support consistent, practical, and patient-centered care and to improve long-term outcomes for adults with UC.
SN  - 1598-9992
SN  - 2233-6869
ER  -